13 results about "Peak plasma" patented technology

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

An indobufen sustained-release formulation, a preparation method therefor, and use thereof. The sustained-release formulation comprises: a main drug, a sustained-release material, a filler, and a binder. The sustained-release formulation achieves slow release of the drug and can continuously and stably release the active ingredient, thereby reducing the peak plasma concentration of the drug, and reducing gastrointestinal irritation. Furthermore, the preparation method is simple and easy to control, and features low cost and good process reproducibility, thus being suitable for large-scale industrial production.

The present invention provides methods, compositions, devices, and kits for treating cystinuria or related disorders, in which tiopronin is administered to a patient according to a modified-release strategy that releases tiopronin in critically-spaced, repeated pulses over time, to provide lower peak plasma levels but consistently higher urine levels of the drug for binding cystine. In particular, use of the present modified-release formulations and systems reduce side effects of tiopronin, thereby increasing patient compliance and quality of life, as well as achieving efficacy with less frequent administrations and / or lower total dosages.

Bioequivalence and / or bioavailability data are mandatory for filing of NDA and ANDA. Presently in absence of proper procedures estimates of these data through peak plasma level concentrations and time to reach peak plasma levels are used. The method suffers from the serious drawback that peak plasma levels do not correlate with efficacy due to delay in transfer to tissue sites as well as differences in metabolic patterns in drugs. Here we have devised a novel method for determination of bioavailability and bioequivalence from measurement of threshold times and concentrations, intrinsic activity, and dissociation constants in vivo in humans. The method essentially determines Intrinsic activities and threshold doses through measurement of drug responses in humans and then uses a mathematical expression to determine KD values of drugs, in vivo, in humans. The process may be applied to animals as well. The method would go a long way in evaluation of true bioavailability and bioequivalence and would also be useful in design.

The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and / or seizure disorders with the modified release compositions is also described.

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

This invention provides the use of terazosin or its pharmaceutically acceptable salts in the preparation of medicaments for the prevention and / or treatment of liver fibrosis, relating to the field of biomedical technology. This invention is the first to discover that terazosin or its pharmaceutically acceptable salts can be used to prevent and treat liver fibrosis. It reveals that terazosin or its pharmaceutically acceptable salts can improve the degree of liver fibrosis by improving liver function, reducing the content of α-SMA (a marker of activated hepatic stellate cells) in liver tissue, reducing the content of Col1a1 in liver tissue, and reducing collagen deposition in liver tissue. Furthermore, the liver-targeted sustained-release drug provided by this invention can reduce the peak plasma concentration of terazosin and prolong its plasma half-life, achieving therapeutic effects equivalent to multiple low-dose injections of terazosin, and has broad application prospects.

The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and / or seizure disorders with the modified release compositions is also described.

The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.

The name of the invention is the use of improved release huperzine formulations in higher doses. Pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with high dose modified release compositions of huperzine are disclosed. The pharmaceutical compositions and methods described herein allow for higher dose administration of huperzine while avoiding fast peak plasma levels, thereby avoiding dose-limiting adverse events associated with immediate release formulations.

To provide a method for treating cancer, the method comprising a combination of different forms of treatment including combinations of different therapeutic agents.SOLUTION: The present invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More specifically, the present invention relates to a method for the treatment of a cancer in a patient, the method comprising orally administering an effective dose of docetaxel, and controlling side effects by preventing peak plasma levels of docetaxel that induce the side effects, while maintaining an effective plasma level of docetaxel to eradicate tumor cells.SELECTED DRAWING: None

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.